HBK Investments’s Biogen BIIB Stock Holding History

HBK Investments’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-14,300	Closed	-$3.34M	–	632
2019 Q2	$3.34M	Buy	+14,300	New	+$3.3M	0.03%	296
2018 Q4	–	Sell	-2,500	Closed	-$883K	–	1193
2018 Q3	$883K	Buy	+2,500	New	+$861K	0.01%	767

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HBK Investments's BIIB Position: Q1 2020 in Review

HBK Investments sold out of Biogen (BIIB) in Q1 2020, closing a stake of 29,311 shares — an estimated $8.7M sold.

HBK Investments first reported a position in BIIB in Q2 2013 and held it in 25 quarters. The position peaked at $49.4M in Q1 2018. 1,100 funds tracked by Wall St. Rank hold BIIB as of Q1 2020.

HBK Investments reported no remaining Biogen position as of Q1 2020 after selling out during the quarter.
HBK Investments sold 29,311 Biogen shares in Q1 2020, an estimated $8.7M.
HBK Investments first reported a position in Biogen in Q2 2013 and held it in 25 quarters.
HBK Investments's Biogen position peaked at $49.4M in Q1 2018.
1,100 funds tracked by Wall St. Rank held Biogen as of Q1 2020.

Based on HBK Investments's 13F filing for Q1 2020, filed 15 May 2020.